Dose-Response Study of N,N-Dimethyltryptamine in Humans
1994/02/01 by Ruck J. Strassman · 43 citations
Psychology · Pharmacology, Toxicology and Pharmaceutics · Neuroscience · #Psychedelics and Drug Studies #Forensic Toxicology and Drug Analysis #Neurotransmitter Receptor Influence on Behavior
paper · doi:10.1001/archpsyc.1994.03950020022002
Abstract
BACKGROUND: Validation of animal models of hallucinogenic drugs' subjective effects requires human data. Previous human studies used varied groups of subjects and assessment methods. Rating scales for hallucinogen effects emphasized psychodynamic principles or the drugs' dysphoric properties. We describe the subjective effects of graded doses of N,N-dimethyltryptamine (DMT), an endogenous hallucinogen and drug of abuse, in a group of experienced hallucinogen users. We also present preliminary data from a new rating scale for these effects. METHODS: Twelve highly motivated volunteers received two doses (0.04 and 0.4 mg/kg) of intravenous (IV) dimethyltryptamine fumarate "nonblind," before entering a double-blind, saline placebo-controlled, randomized study using four doses of IV DMT. Subjects were carefully interviewed after resolution of drug effects, providing thorough and systematic descriptions of DMT's effects. They also were administered a new instrument, the Hallucinogen Rating Scale (HRS). The HRS was drafted from interviews obtained from an independent sample of 19 experienced DMT users, and modified during early stages of the study. RESULTS: Psychological effects of IV DMT began almost immediately after administration, peaked at 90 to 120 seconds, and were almost completely resolved by 30 minutes. This time course paralleled DMT blood levels previously described. Hallucinogenic effects were seen after 0.2 and 0.4 mg/kg of dimethyltryptamine fumarate, and included a rapidly moving, brightly colored visual display of images. Auditory effects were less common. "Loss of control," associated with a brief, but overwhelming "rush," led to a dissociated state, where euphoria alternated or coexisted with anxiety. These effects completely replaced subjects' previously ongoing mental experience and were more vivid and compelling than dreams or waking awareness. Lower doses, 0.1 and 0.05 mg/kg, were primarily affective and somaesthetic, while 0.1 mg/kg elicited the least desirable effects. Clustering of HRS items, using either a clinical, mental status method or principal components factor analysis provided better resolution of dose effects than did the biological variables described previously. CONCLUSIONS: These clinical and preliminary quantitative data provide bases for further psychopharmacologic characterization of DMT's properties in humans. They also may be used to compare the effects of other agents affecting relevant brain receptors in volunteer and psychiatric populations.
Citations
Cited by
- Are psychedelic medicines the reset for chronic pain? Preliminary findings and research needs
- Psychedelics
- Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance
- Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects
- The phenomenology of psychedelic temporality: current knowledge, open questions, and clinical applications
- Personalised Perception: The Effect of Personality on the Sensory Effects of Psychedelics
- Safety, tolerability and subjective effects of vaporized N,N-Dimethyltryptamine: A randomized double-blind clinical trial
- Network control energy reductions under DMT relate to serotonin receptors, signal diversity, and subjective experience
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial
- Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences
- Phenomenology, Structure, and Dynamic of Psychedelic States
- An encounter with the self: A thematic and content analysis of the DMT experience from a naturalistic field study
- Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later
- Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
- The emerging science of microdosing: A systematic review of research on low dose psychedelics (1955–2021) and recommendations for the field
- Human hallucinogen research: guidelines for safety
- Absolute Oral Bioavailability and Bioequivalence of LSD Base and Tartrate in a Double‐Blind, Placebo‐Controlled, Crossover Study
- Dimethyltryptamine [wikipedia]
- The behavioral pharmacology of hallucinogens. [europepmc]
- Human hallucinogen research: guidelines for safety. [europepmc]
- Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. [europepmc]
- Psychometric evaluation of the altered states of consciousness rating scale (OAV). [europepmc]
- Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. [europepmc]
- Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. [europepmc]
- Dose-related behavioral, subjective, endocrine, and psychophysiological effects of the κ opioid agonist Salvinorin A in humans. [europepmc]
- Recent advances in the neuropsychopharmacology of serotonergic hallucinogens. [europepmc]
- Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. [europepmc]
- Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin. [europepmc]
- Neuropharmacology of N,N-dimethyltryptamine. [europepmc]
- Ego-Dissolution and Psychedelics: Validation of the Ego-Dissolution Inventory (EDI). [europepmc]
- Clinical applications of hallucinogens: A review. [europepmc]
- Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. [europepmc]
- The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms. [europepmc]
- Effects of N, N-Dimethyltryptamine on Rat Behaviors Relevant to Anxiety and Depression. [europepmc]
- Psychedelics Promote Structural and Functional Neural Plasticity. [europepmc]
- Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. [europepmc]
- DMT Models the Near-Death Experience. [europepmc]
- Psychedelics, Meditation, and Self-Consciousness. [europepmc]
- Chronic, Intermittent Microdoses of the Psychedelic N , N -Dimethyltryptamine (DMT) Produce Positive Effects on Mood and Anxiety in Rodents. [europepmc]
- Neural correlates of the DMT experience assessed with multivariate EEG. [europepmc]
- Predicting Reactions to Psychedelic Drugs: A Systematic Review of States and Traits Related to Acute Drug Effects. [europepmc]
- Exploratory study of the dose-related safety, tolerability, and efficacy of dimethyltryptamine (DMT) in healthy volunteers and major depressive disorder. [europepmc]
- Psychedelics, Mystical Experience, and Therapeutic Efficacy: A Systematic Review. [europepmc]
Related